A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder
Introduction: Darifenacin and trospium are the commonly used antimuscarinics in the management of overactive bladder (OAB). Constipation is the second most common treatment related sideeffect. Though its incidence with the above two medications is known, data on their comparative severity and imp...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5677/11884_CE(RA1)_F(T)_PF1(PAK)_PFA(AK)_PF2(PAG)_u.pdf |
| _version_ | 1818521283227287552 |
|---|---|
| author | Revanna Manjunatha Hulikallu Purushotama Pundarikaksha Basavanahalli Krishnaiah Hanumantharaju Satenahalli Javaregowda Anusha |
| author_facet | Revanna Manjunatha Hulikallu Purushotama Pundarikaksha Basavanahalli Krishnaiah Hanumantharaju Satenahalli Javaregowda Anusha |
| author_sort | Revanna Manjunatha |
| collection | DOAJ |
| description | Introduction: Darifenacin and trospium are the commonly used
antimuscarinics in the management of overactive bladder (OAB).
Constipation is the second most common treatment related sideeffect. Though its incidence with the above two medications is
known, data on their comparative severity and impact on patient’s
well-being is lacking.
Materials and Methods: Sixty subjects with OAB included in the
study were randomized in 1:1 fashion to receive either darifenacin
7.5 mg OD or trospium extended release 60 mg OD. Treatment
response was monitored using overactive bladder symptom
score (OABSS). The severity of constipation was assessed using
McMillan & Williams Constipation assessment scale (CAS), Bristol
stool form scale and Knowles-Eccersley-Scott-Symptom (KESS)
questionnaire score administered at baseline, 2 and 4 weeks of
treatment.
Results: OABSS improved significantly, -5.80 ± 3.99 (p = 0.0005)
and -5.27 ± 2.98 (p = 0.0005) in darifenacin and trospium groups
respectively. However, the difference between the two groups
was not significant either at 2 weeks (p = 0.952) or 4 weeks (p =
0.654) of treatment. A significant decrease in stool consistency
was noted with darifenacin treatment (p < 0.05), but the same
was not seen with trospium (p = 0.076). There was no significant
difference in scores of KESS questionnaire between baseline,
2 weeks and 4 weeks, both within the group and between the
groups (p > 0.05). McMillan & Williams CAS scores increased
at week 2 and week 4, in comparison with baseline scores in
both darifenacin and trospium treated patients, however, the
difference between the two groups was not statistically significant
(p > 0.05).
Conclusion: Darifenacin and trospium are equally efficacious and
comparable in tolerability in terms of constipation severity and its
impact on patient well-being. |
| first_indexed | 2024-12-11T01:48:58Z |
| format | Article |
| id | doaj.art-a884a8c0d6154ad3baf38a72c9077934 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-11T01:48:58Z |
| publishDate | 2015-03-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-a884a8c0d6154ad3baf38a72c90779342022-12-22T01:24:48ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2015-03-0193FC05FC0910.7860/JCDR/2015/11884.5677A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive BladderRevanna Manjunatha0Hulikallu Purushotama Pundarikaksha1Basavanahalli Krishnaiah Hanumantharaju2Satenahalli Javaregowda Anusha3Post-graduate Cum Tutor, Department of Pharmacology, Kempegowda Institute of Medical Sciences, Banashankari 2nd stage, Bangalore, India.Professor and Head, Department of Pharmacology, Kempegowda Institute of Medical Sciences, Banashankari 2nd stage, Bangalore, India.Consultant Urologist, Department of Urology, Surgical Superspecialities, KIMS Hospital and Research Centre, V V Puram, Bangalore, India.Post-graduate Cum Tutor, Department of Pharmacology, Kempegowda Institute of Medical Sciences, Banashankari 2nd stage, Bangalore, India.Introduction: Darifenacin and trospium are the commonly used antimuscarinics in the management of overactive bladder (OAB). Constipation is the second most common treatment related sideeffect. Though its incidence with the above two medications is known, data on their comparative severity and impact on patient’s well-being is lacking. Materials and Methods: Sixty subjects with OAB included in the study were randomized in 1:1 fashion to receive either darifenacin 7.5 mg OD or trospium extended release 60 mg OD. Treatment response was monitored using overactive bladder symptom score (OABSS). The severity of constipation was assessed using McMillan & Williams Constipation assessment scale (CAS), Bristol stool form scale and Knowles-Eccersley-Scott-Symptom (KESS) questionnaire score administered at baseline, 2 and 4 weeks of treatment. Results: OABSS improved significantly, -5.80 ± 3.99 (p = 0.0005) and -5.27 ± 2.98 (p = 0.0005) in darifenacin and trospium groups respectively. However, the difference between the two groups was not significant either at 2 weeks (p = 0.952) or 4 weeks (p = 0.654) of treatment. A significant decrease in stool consistency was noted with darifenacin treatment (p < 0.05), but the same was not seen with trospium (p = 0.076). There was no significant difference in scores of KESS questionnaire between baseline, 2 weeks and 4 weeks, both within the group and between the groups (p > 0.05). McMillan & Williams CAS scores increased at week 2 and week 4, in comparison with baseline scores in both darifenacin and trospium treated patients, however, the difference between the two groups was not statistically significant (p > 0.05). Conclusion: Darifenacin and trospium are equally efficacious and comparable in tolerability in terms of constipation severity and its impact on patient well-being.https://jcdr.net/articles/PDF/5677/11884_CE(RA1)_F(T)_PF1(PAK)_PFA(AK)_PF2(PAG)_u.pdfantimuscarinicsbristol stool form scalecaskess |
| spellingShingle | Revanna Manjunatha Hulikallu Purushotama Pundarikaksha Basavanahalli Krishnaiah Hanumantharaju Satenahalli Javaregowda Anusha A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder Journal of Clinical and Diagnostic Research antimuscarinics bristol stool form scale cas kess |
| title | A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder |
| title_full | A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder |
| title_fullStr | A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder |
| title_full_unstemmed | A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder |
| title_short | A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder |
| title_sort | prospective comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder |
| topic | antimuscarinics bristol stool form scale cas kess |
| url | https://jcdr.net/articles/PDF/5677/11884_CE(RA1)_F(T)_PF1(PAK)_PFA(AK)_PF2(PAG)_u.pdf |
| work_keys_str_mv | AT revannamanjunatha aprospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT hulikallupurushotamapundarikaksha aprospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT basavanahallikrishnaiahhanumantharaju aprospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT satenahallijavaregowdaanusha aprospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT revannamanjunatha prospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT hulikallupurushotamapundarikaksha prospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT basavanahallikrishnaiahhanumantharaju prospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder AT satenahallijavaregowdaanusha prospectivecomparativestudyoftheoccurrenceandseverityofconstipationwithdarifenacinandtrospiuminoveractivebladder |